RVL Pharmaceuticals plc (RVLPQ)
RVL Pharmaceuticals plc operates in the Biotechnology industry of the Healthcare sector, headquartered in Bridgewater, NJ, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $3.1M. On trailing twelve-month figures it carries a trailing P/E of -0.05, a net margin of -104.0%. Its beta of 8.91 implies it has historically moved more than the broad market.
RVL Pharmaceuticals plc operates as a specialized drug company, dedicated to innovating and marketing pharmaceutical solutions for patient groups with unmet needs in the ophthalmic and medical aesthetics domains. The firm's activities extend across the United States, Argentina, and Hungary. Its principal commercial offering is Upneeq (RVL-1201), an ophthalmic solution containing oxymetazoline hydrochloride, specifically formulated to address acquired blepharoptosis, or drooping eyelids, in adults. The company, formerly known as Osmotica Pharmaceuticals plc, officially rebranded to RVL Pharmaceuticals plc in January 2022. Its corporate headquarters are situated in Bridgewater, New Jersey.
RVL Pharmaceuticals plc is most often compared with the following Healthcare names: